In this Healio Video Perspective from the AAO meeting, Diana V. Do, MD, overviews positive 96-week efficacy and safety data from the PHOTON study investigating aflibercept 8 mg in patients with diabetic macular edema.
Patients randomized to aflibercept 8 mg were dosed every 12 or 16 weeks, while patients randomized to aflibercept 2 mg were dosed every 2 months.
“The results showed that aflibercept 8 mg met its primary endpoint, and the visual acuity was noninferior to 2 milligrams of aflibercept at week 48,” she said. “In addition, when we (Read more...)